Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002505 · ClinicalTrials.gov registry record · Phase 2
Tumor Cell Vaccine in Treating Patients With Advanced Cancer
A Phase 2 study, sponsored by Hoag Memorial Hospital Presbyterian.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00002505 is a Phase 2 study that has completed, run by Hoag Memorial Hospital Presbyterian.
The verdict
NCT00002505, a Phase 2 study, has completed, sponsored by Hoag Memorial Hospital Presbyterian.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Vaccines made from the patient's cancer cells may make the body build an immune response and kill their tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of autologous tumor cell vaccination plus immunologic adjuvant in treating patients who have metastatic cancer.
Interventions
- BIOLOGICAL filgrastim
- BIOLOGICAL recombinant interferon gamma
- BIOLOGICAL tumor cell lysate vaccine therapy
Trial Details
| Field | Value |
|---|---|
| Start Date | 1992-08 |
| Est. Completion | 2006-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002505
The ClinicalTrials.gov registry entry for NCT00002505 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Hoag Memorial Hospital Presbyterian, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which filgrastim is the first listed.
NCT00002505 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002505 about?
NCT00002505 is a clinical study titled "Tumor Cell Vaccine in Treating Patients With Advanced Cancer". RATIONALE: Vaccines made from the patient's cancer cells may make the body build an immune response and kill their tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of autologous tumor cell vaccination plus immunologic adjuvant in treating patients who have metastatic cance...
What is the current status of trial NCT00002505?
This trial is currently completed. It is a Phase 2 study. The study started on 1992-08. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00002505?
The interventions under investigation include: filgrastim (BIOLOGICAL), recombinant interferon gamma (BIOLOGICAL), tumor cell lysate vaccine therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002505?
This trial is sponsored by Hoag Memorial Hospital Presbyterian, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.